逆相タンパク質アレイに基づくタンパク質発現解析:細胞溶解物からの複数のタンパク質の発現の同時定量化のための手順

Executive Industry Relevance

Reverse Phase Protein Arrays (RPPA) enable high-throughput quantification of protein expression from complex lysates, supporting target validation in oncology drug discovery. The method provides quantitative, reproducible data across hundreds of samples, facilitating mechanistic de-risking and predictive confidence in early-stage target selection. By enabling parallel analysis of signaling pathways and post-translational modifications, RPPA aids in prioritizing targets with strong biological rationale before lead identification.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses by quantifying multiple proteins simultaneously from heterogeneous tumor lysates.
• Operational Value: Supports biological de-risking through reproducible, multiplexed protein profiling across sample cohorts.
• Predictive Value: Generates quantitative expression data that supports target confidence and portfolio triage decisions.

Screening & Assay Development

• Assay Readiness: Produces standardized, quantitative protein expression readouts suitable for downstream screening applications.
• Reproducibility: Utilizes triplicate spotting and serial dilution to ensure data reliability and inter-assay consistency.
• Scalability: Compatible with robotic spotting (e.g., MicroGrid II) and multi-pad slide formats for high-throughput processing.

Translational & Preclinical Research

• Translational Continuity: Enables alignment of discovery-phase protein expression changes with preclinical biomarker validation.
• Mechanistic De-risking: Supports pathway analysis and target modulation assessment in disease-relevant systems.
• Risk-Adjusted Advancement: Provides expression data that informs go/no-go decisions based on target engagement and pathway effects.

Pipeline & Workflow Integration

RPPA fits within the discovery continuum from target hypothesis testing through lead identification, providing quantitative protein data that informs early decision-making.

• Discovery Biology: Supports hypothesis testing and pathway clarification via multiplexed protein quantification from cell lysates.
• Screening: Delivers standardized, reproducible protein expression outputs that enable reliable compound effect assessment.
• Analytics: Generates fluorescent signal intensities that serve as quantitative readouts for comparing protein expression across conditions.
• Translational Research: Connects discovery-phase protein profiles to preclinical continuity through biomarker-aligned expression patterns.
• Enterprise Reuse: Functions as a reusable platform for protein profiling across multiple projects and target classes.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence by reducing mechanistic ambiguity in target validation.
• Operational Value: Ensures standardization and reproducibility through controlled spotting, blocking, and washing steps.
• Strategic Value: Improves go/no-go decision quality and capital efficiency by de-risking biological hypotheses early.
• Portfolio Impact: Enables risk-adjusted prioritization of targets based on quantitative protein expression and pathway data.

Implementation Considerations

• Requires expertise in protein lysate preparation, antibody validation, and fluorescent detection.
• Depends on robotic spotting equipment (e.g., MicroGrid II) and fluorescent scanners capable of 680nm/800nm detection.
• Necessitates standardized protocols for blocking, antibody incubation, and washing to minimize variability.
• Involves adaptation considerations when applying to different sample types (e.g., tissue vs. cell lysate) and antibody panels.
• Limited by the need for high-quality, specific antibodies and careful optimization of dilution series to avoid signal saturation.

Biopharma FAQs